OKYO Pharma
  • Home
  • About
    • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Neuropathic Corneal Pain
    • Non-infectious Anterior Uveitis
    • Allergic Conjunctivitis 
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Investors
    • Share Information
    • Shareholder Services
    • Investor Presentation
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
    • FAQs
  • News
    • Press releases
    • Media
  • Contact
  • Linkedin
  • Twitter
Select Page

World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma

by admin | 23rd February 2023 | News

OKYO Pharma Announces Appointment of Dr. Jay S. Pepose to its Scientific Advisory Board World-renowned Ophthalmologist with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Joins Advisory Board of OKYO Pharma London and New York, NY, February...

Recent Posts

  • OKYO Pharma Granted U.S. Patent Covering OK-101’s Potential for Treating Symptoms of Dry Eye Disease
  • OKYO Pharma CEO Interview to Air on Bloomberg TV
  • OKYO Pharma Announces Chairman Acquires Shares
  • OKYO Pharma Announces Chairman Acquires Shares
  • OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Recent Comments

No comments to show.
OKYO PHARMA

Explore

  • About
  • Disease Focus
  • Technology
  • Pipeline
  • Investors
  • News
  • Contact

Legal

  • Legal
  • Privacy Policy

Follow

  • Follow
  • Follow

© OKYO Pharma, Limited | 2023